Abstract:Meconium aspiration syndrome (MAS) is an important cause of respiratory distress in the term infant. Therapy for the disease remains problematic, and newer treatments such as high-frequency ventilation and inhaled nitric oxide are being applied with increasing frequency. There is a significant disturbance of the pulmonary surfactant system in MAS, with a wealth of experimental data indicating that inhibition of surfactant function in the alveolar space is an important element of the pathophysiology of the disease. This inhibition may be mediated by meconium, plasma proteins, haemoglobin and oedema fluid, and, at least in vitro, can be overcome by increasing surfactant phospholipid concentration. These observations have served as the rationale for administration of exogenous surfactant preparations in MAS, initially as standard bolus therapy and, more recently, in association with therapeutic lung lavage. Bolus surfactant therapy in ventilated infants with MAS has been found to improve oxygenation in most studies, although there are a significant proportion of nonresponders and in many cases the effect is transient. Pooled data from randomised controlled trials of surfactant therapy suggest a benefit in terms of a reduction in the requirement for extracorporeal membrane oxygenation (relative risk 0.48 in surfactant-treated infants) but no diminution of air leak or ventilator days. Current evidence would support the use of bolus surfactant therapy on a case by case basis in nurseries with a relatively high mortality associated with MAS, or the lack of availability of other forms of respiratory support such as high-frequency ventilation or nitric oxide. If used, bolus surfactant should be administered as early as practicable to infants who exhibit significant parenchymal disease, at a phospholipid dose of at least 100 mg/kg, rapidly instilled into the trachea. Natural surfactant or a third-generation synthetic surfactant should be used and the dosage repeated every 6 hours until oxygenation has improved. Lung lavage with dilute surfactant has recently emerged as an alternative to bolus therapy in MAS, which has the advantage of removing surfactant inhibitors from the alveolar space in addition to augmenting surfactant phospholipid concentration. Combined animal and human data suggest that lung lavage can remove significant amounts of meconium and alveolar debris, and thereby improve oxygenation and pulmonary mechanics. Arterial oxygen saturation inevitably falls during lavage but has been noted to recover relatively rapidly, even in infants with severe disease. Several randomised controlled trials of surfactant lavage in MAS are underway, and until the results are known, lavage must be considered an unproven and experimental therapy.

Clinical considerations when treating neonatal aspiration syndromes

[Clinical Epidemiological Characteristics of Neonatal Respiratory Failure: an Analysis of 1,108 Neonates].

Acute respiratory distress syndrome: A review of ARDS across the life course

Aerosolized surfactants

Clinical features and prognosis of severe meconium aspiration syndrome with acute respiratory distress syndrome

Adult respiratory distress syndrome in pediatric patients. II. Management

Management of the acute respiratory distress syndrome

Safe emergency neonatal airway management: current challenges and potential approaches

Pneumomediastinum and pneumothorax in acute respiratory distress syndrome (ARDS) patients: a narrative review

Aspiration after Anesthesia: Chemical versus Bacterial, Differential Diagnosis, Management, and Prevention

Advances in the Management of Meconium Aspiration Syndrome

[Clinical Assessment and Related Intervention of Neonatal Upper Airway Obstruction].

Can we balance early exogenous surfactant therapy and non-invasive respiratory support to optimise outcomes in extremely preterm infants? A nuanced review of the current literature

Chronic neonatal lung disease: time to look beyond the alveolus

Neonatal pulmonology: optimizing transition and lung function in preterm infants

State of the art on neonatal noninvasive respiratory support: How physiological and technological principles explain the clinical outcomes

Meconium aspiration syndrome: a comprehensive review

Noninvasive Respiratory Support for Pediatric Critical Asthma

Respiratory issues in the management of children with neuromuscular disease

Surfactant therapy for meconium aspiration syndrome: current status

Laryngeal Mask for Minimally-Invasive Surfactant Administration: A Narrative Review